Role of G2-S16 Polyanionic Carbosilane Dendrimer in the Prevention of Respiratory Syncytial Virus Infection In Vitro and In Vivo in Mice
| Autor: | Rosa Rodriguez-Fernández, María Jesús Serramía, Ignacio Rodriguez-Izquierdo, Mariángeles Muñoz-Fernández, Rafael Ceña-Diez, Isidoro Martínez |
|---|---|
| Přispěvatelé: | Instituto de Salud Carlos III, Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Centro de Investigación Biomédica en Red - CIBERBBN (Bioingeniería, Biomateriales y Nanomedicina), Unión Europea. European Cooperation in Science and Technology (COST), Polish National Agency for Academic Exchange |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Polymers and Plastics
viruses Organic chemistry 02 engineering and technology Syncytium Article Virus 03 medical and health sciences QD241-441 In vivo Dendrimer Nanotechnology Receptor RSV infection 030304 developmental biology chemistry.chemical_classification 0303 health sciences nanotechnology Chemistry Respiratory infection General Chemistry respiratory system 021001 nanoscience & nanotechnology Virology In vitro G2-S16 dendrimer 0210 nano-technology Glycoprotein syncytium |
| Zdroj: | Polymers, Vol 13, Iss 2141, p 2141 (2021) Repisalud Instituto de Salud Carlos III (ISCIII) Polymers Volume 13 Issue 13 |
| Popis: | The respiratory syncytial virus (RSV) causes respiratory infection and bronchiolitis, requiring hospitalization mainly in infants. The interaction between RSV, envelope glycoproteins G and F, and cell surface heparan sulfate proteoglycans (HSPG) is required for binding and entry into the host cells. A G2-S16 polyanionic carbosilane dendrimer was identified as a possible RSV inhibitor. We speculated that the G2-S16 dendrimer adheres to the host cell-surface HSPG, acts through binding to HS receptors, and prevents further RSV infection. The G2-S16 dendrimer was non-toxic when applied intranasally to Balb/c mice, and interestingly enough, this G2-S16 dendrimer inhibits 85% RSV. Therefore, our G2-S16 dendrimer could be a candidate for developing a new possible therapy against RSV infection. This work has been (partially) funded by the RD16/0025/0019, projects as part of Acción Estratégica en Salud, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (2013–2016) and co-financed by Instituto de Salud Carlos III (Subdirección General de Evaluación) and Fondo Europeo de Desarrollo Regional (FEDER), RETIC PT17/0015/0042, Fondo de Investigacion Sanitaria (FIS) (grant number PI19/01638) and EPIICAL project. CIBER-BBN is an initiative funded by the VI National R&D&i Plan 2008–2011, Iniciativa Ingenio 2010, the Consolider Program, and CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. This work has been supported partially by the EUROPARTNER: Strengthening and spreading international partnership activities of the Faculty of Biology and Environmental Protection for interdisciplinary research and innovation of the University of Lodz Programme: NAWA International Academic Partnership Programme. This article/publication is based upon work from COST Action CA 17140 “Cancer Nanomedicine from the Bench to the Bedside” supported by COST (European Cooperation in Science and Technology). Sí |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|